GHI

YourCoach.Health Appoints Four New Members to Board of Advisors

Retrieved on: 
星期二, 三月 8, 2022
Health, Northwestern University, COO, CEO, AIG, Employee benefits, Optum, World, Central Waqf Council, Taranto, Industry, Kellogg School of Management, Growth, United Nations, Johnson & Johnson, Board, Willis Group, Cigna, World Health Organization, Insurance, Practice management, Northwestern University School of Education and Social Policy, GHI, Burns, Pharmaceutical industry, Management

"It's a privilege to welcome these esteemed individuals to our advisory board.

Key Points: 
  • "It's a privilege to welcome these esteemed individuals to our advisory board.
  • Each brings decades of experience and a background that's uniquely positioned to drive the growth of our multifaceted organization," said Marina Borukhovich, CEO & Founder of YourCoach.Health.
  • Dr. Kate Wolin is an entrepreneurial executive and behavioral epidemiologist with an expansive career in academia and consumer health.
  • We're confident that our advisory board will help champion health coaches as changemakers in the health and wellness industries."

CancerIQ Raises $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

Retrieved on: 
星期四, 三月 3, 2022
Oncology, Health, Security, Technology, Practice Management, Software, Biotechnology, Risk, Genomics, OSF, Risk assessment, Patient, Research, Gaps, Genetics, Population, Twitter, Quality of life, EHR, Breast cancer, Academic health science centre, Merck, LinkedIn, Behavior, EMR, Series, Map, Ebook, Multimedia, COVID-19, Cancer, Disease, OSF HealthCare, GHI, CEO, General partnership, Female, Partnership, MD, Genetic testing, Pharmaceutical industry, Hospital, Medical imaging, Management, Facebook

McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQs Series A lead investor, HealthX Ventures, also participated in the Series B round.

Key Points: 
  • McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQs Series A lead investor, HealthX Ventures, also participated in the Series B round.
  • Systemic access barriers have created stark inequality when it comes to preventive cancer care in the United States.
  • The cancer research community has made great strides in cancer prevention and treatment, said Olufunmilayo (Funmi) Olopade, MD, Co-founder and Chief Scientific Advisor of CancerIQ.
  • CancerIQs vision is to end cancer as we know it by eliminating health disparities and democratizing access to the latest advances in cancer early detection and prevention, added Feyi Olopade Ayodele, Co-founder and CEO of CancerIQ.

Green Hydrogen International Announces Hydrogen City, Texas - The World's Largest Green Hydrogen Production and Storage Hub

Retrieved on: 
星期四, 三月 3, 2022
Hydrogen, Leadership, Plant, Cave, Hydrogen internal combustion engine vehicle, Ministry of Economy, Trade and Industry, Ammonia, Sustainability, Ministry, Aviation, METI, Port of Brownsville, Map, Port, Maxwell, GHI, Farmer, ERCOT, Natural gas, SAF, Wind, Technology, CO2, Power, Oil, Renewable energy, Jet fuel, Coal, Industry

AUSTIN, Texas, March 3, 2022 /PRNewswire/ -- Green Hydrogen International (GHI) has unveiled plans to create the world's largest green hydrogen production and storage hub in South Texas.

Key Points: 
  • AUSTIN, Texas, March 3, 2022 /PRNewswire/ -- Green Hydrogen International (GHI) has unveiled plans to create the world's largest green hydrogen production and storage hub in South Texas.
  • Hydrogen City, Texas will be an integrated green hydrogen production, storage, and transport hub growing to 60GW in size and producing over 2.5 billion kilograms of green hydrogen per year.
  • "Hydrogen City is a massive, world class undertaking that will put Texas on the map as a leading green hydrogen producer.
  • Access to salt storage is critical to the scaling-up of green hydrogen production as it allows for maximum utilization of electrolysers and serves as a buffer between variable wind and solar production and final delivery of green hydrogen to customers.

PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders to Commercialize Cancer Risk Stratification Services to Support Better Patient Insights and Outcomes

Retrieved on: 
星期二, 一月 11, 2022
Research, Division, Mount Sinai Health System, Intelligence, Urology, Hospital, Mount Sinai Hospital, Cancer, Journal of Neurology, Neurosurgery, and Psychiatry, Ophthalmology, Technology, Wheaton Industries, Death, Icahn School of Medicine at Mount Sinai, No, Oncology, Digital health, Agilent Technologies, Company, Doctor of Philosophy, BD (company), Multimedia, Mount Sinai Kravis Children's Hospital, Patient, Health, U.S. News & World Report, Mount Sinai Hospital (Manhattan), World, Recurrence, National, News, GHI, Investment, Marie Cassidy, Rehabilitation, National Institutes of Health, Breast cancer, Digital, HIV disease progression rates, Health system, YouTube, Attention, Pathology, Twitter, Newsweek, Physician, Pharmaceutical industry, Medical imaging, Geriatrics, Merck, Orthopedic surgery, Facebook, Medicine, Gastroenterology

Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development.

Key Points: 
  • Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development.
  • The use of morphology features to stratify cancer risk provides valuable insights into cancer treatment, attracting the attention of healthcare innovators.
  • The funding will be used to support the development and commercialization of additional cancer diagnostics and clinical trial testing.
  • PreciseDx was established to improve the quality of cancer treatment for all patients through our risk stratification platform.

Verge Genomics Secures $98 Million in New Financing

Retrieved on: 
星期四, 十二月 16, 2021
Biotechnology, Health, Pharmaceutical, Other Technology, Technology, Tao, Lilly, BlackRock, Series, Company, Genomics, ALS, Eli Lilly and Company, Venture round, LLC, Health, Drug discovery, CEO, Machine learning, Vulcan Inc., Artificial intelligence, Patient, Drug development, Neuroscience, Section 32, Verge, Efficiency, Investment, Program, GHI, Digital health, Amyotrophic lateral sclerosis, Partnership, Digital, Technology, Pharmaceutical industry, Medical device, Merck, Verge Genomics, Merck Global Health Innovation Fund, VERGE GENOMICS, MERCK GLOBAL HEALTH INNOVATION FUND

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.

Key Points: 
  • Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing.
  • Verge has built an end-to-end, AI-driven drug discovery platform that includes one of the fields largest proprietary genomic datasets from human brain tissue.
  • Verge has built an end-to-end drug discovery and development platform, featuring one of the fields largest and most comprehensive proprietary patient genomics datasets in neuroscience.
  • www.merckghifund.com
    Shumaker, Loop & Kendrick LLP and Green Shoots Consulting, LLC acted as advisors to Merck GHI in connection with the Verge Genomics transaction.

UGI and Global Common Energy Announce Third RNG Project in Upstate New York

Retrieved on: 
星期二, 十月 26, 2021
Energy, Other Energy, Utilities, Oil, Gas, RNG, EPC, John Allen Farm Massacre, Farm, Engineering, Natural gas, Finger Lakes, UGI Corporation, Contract, GCE, Family, Calendar, NYSE, LPG, Cayuga, UGI, LLC, Â, GHI, Peck, Manure, Mid-Atlantic (United States), Professional, Animal, Renewable energy

Cayuga RNG has entered into an agreement to develop its third project to produce renewable natural gas (RNG) in upstate New York.

Key Points: 
  • Cayuga RNG has entered into an agreement to develop its third project to produce renewable natural gas (RNG) in upstate New York.
  • Cayuga RNG is a joint venture of UGI Energy Services, LLC (UGIES), a subsidiary of UGI Corporation (NYSE: UGI ), and Global Common Energy, LLC (GCE).
  • Cayuga RNGs third project will be constructed at El-Vi Farms, which is located on the border of Wayne and Ontario counties in upstate New York.
  • GCE establishes Strategic Energy Partnerships with our clients to design and implement energy projects that meet their business objectives.

Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

Retrieved on: 
星期三, 十月 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, General Health, Professional Services, Venture Capital, Clinical Trials, Other Technology, Biotechnology, Science, Software, Other Science, Internet, Research, Health, Cloud, Clinical trial, CG, NASDAQ, Guggenheim, Martha Plimpton, Digital, LSAC, View, Data management, COVID-19, EFront Alternative Investment Solutions, GHI, Drug development, Health, Oliver Cromwell, Digital health, Research, Vaccine, CEO, Solution, Patient, NDAS, Industry, Â, HarbourVest Global Private Equity, Partnership, Investment, Sullivan & Cromwell, Company, Pharmaceutical industry, Saama Technologies, Inc., Carlyle, Merck Global Health Innovation Fund, SAAMA TECHNOLOGIES, INC., CARLYLE, MERCK GLOBAL HEALTH INNOVATION FUND

Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.

Key Points: 
  • Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.
  • The partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.
  • Saamas intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
  • This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saamas leadership of this new era and the promise offered by our state-of-the-art solutions.

Octave Bioscience Announces Strategic Investment from the Merck Global Health Innovation Fund to Transform Disease Measurement and Care for Patients with Neurodegenerative Diseases

Retrieved on: 
星期二, 十月 12, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Population health, Brain, Inflammation, Digital health, Health, Biology, Digital, Neurology, Decision-making, MS, Physician, Spine, List of life sciences, GHI, Industry, HIV disease progression rates, Neurodegeneration, Population, Investment, MRI, Multiple sclerosis, Founder, CNS, Patient, View, Pharmaceutical industry, Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience, Merck Global Health Innovation Fund, THE OCTAVE BIOSCIENCE COMPREHENSIVE CARE PLATFORM, OCTAVE BIOSCIENCE, MERCK GLOBAL HEALTH INNOVATION FUND

Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.

Key Points: 
  • Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.
  • Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.
  • Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.

UGI Partners with California Bioenergy and Sevana Bioenergy to Develop RNG Dairy Digester Projects in South Dakota Through MBL Bioenergy

Retrieved on: 
星期四, 九月 16, 2021
Other Energy, Environment, Alternative Energy, Agriculture, Energy, Natural Resources, California Department of Food and Agriculture, District, Investment, LPG, CEO, Mid-Atlantic (United States), USDA, Engineering, Electricity, Digestion, Methane, Economics, Natural gas, California Public Utilities Commission, Â, California Energy Commission, Carbon, Calendar, LLC, MBL, NYSE, UGI, GHI, Soil, Environment, Solution, Water quality, Partnership, UGI Corporation, California Air Resources Board, RNG, Renewable energy, UGI Corporation, CalBio, Sevana, UGI CORPORATION, CALBIO, SEVANA

MBL Bioenergy, LLC (MBL Bioenergy) announced today that it has entered into definitive agreements to develop several clusters of dairy farm digester projects to produce renewable natural gas (RNG) from multiple farms in South Dakota.

Key Points: 
  • MBL Bioenergy, LLC (MBL Bioenergy) announced today that it has entered into definitive agreements to develop several clusters of dairy farm digester projects to produce renewable natural gas (RNG) from multiple farms in South Dakota.
  • MBL Bioenergy is a joint venture funded by UGI Energy Services, LLC (UGIES) as well as subsidiaries of California Bioenergy LLC (CalBio) and Sevana Bioenergy, LLC (Sevana Bioenergy).
  • MBL Bioenergy combines the experience and expertise of UGIES and two premier dairy digester project development companies, California Bioenergy and Sevana Bioenergy.
  • In totality, the projects will represent over $100 million investment in RNG by MBL Bioenergy, with funding by UGIES on a per project basis.

UGI and Global Common Energy Add a Second Renewable Natural Gas Project in Upstate New York

Retrieved on: 
星期二, 九月 7, 2021
Energy, Utilities, Oil, Gas, UGI Corporation, GCE, Spruce Haven Farm, Allen Farms, UGI CORPORATION, GCE, SPRUCE HAVEN FARM, ALLEN FARMS

Cayuga RNG Holdings, LLC (Cayuga RNG) announced today that it has entered into an agreement to develop its second project to produce renewable natural gas (RNG) in upstate New York.

Key Points: 
  • Cayuga RNG Holdings, LLC (Cayuga RNG) announced today that it has entered into an agreement to develop its second project to produce renewable natural gas (RNG) in upstate New York.
  • Cayuga RNG is a joint venture of UGI Energy Services, LLC (UGIES), a subsidiary of UGI Corporation (NYSE: UGI ), and Global Common Energy, LLC (GCE).
  • Cayuga RNGs second project will be located at Allen Farms, which is approximately five miles from Spruce Haven.
  • Allen Farms has contracted with Cayuga RNG to supply dairy waste that will serve as the feedstock for renewable natural gas.